This phase I/II study is seeking to determine the best dose level, safety and effect, of a new cancer drug (DYP688) in people with metastatic ocular (uveal) melanoma.
This trial is treating patients with metastatic uveal (ocular) melanoma, and other melanomas harbouring GNAQ/11 mutations.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas
There will be two parts to this study: a phase I, dose escalation part followed by a phase II part. Dose escalation will be conducted in people with metastatic uveal melanoma (MUM) and other melanomas with GNAQ/11 mutations. Once the maximum tolerated dose (MTD) and/or recommended doses (RD) is determined in the dose escalation part, the study may continue with a phase II part. The phase II part will be conducted in two groups of participants with MUM, a group that has received prior treatment with tebentafusp, and a group that has not received prior treatment with tebentafusp. In addition to MUM, a third group of participants with a non-uveal GNAQ/11 mutant melanomas may also be explored. This cohort may be opened based on emerging data from teh dose escalation part of the study.
Recruiting Hospitals Read More